Circassia’s recent interims demonstrated 55% y-o-y revenue growth to £28.4m and a 75% R&D expense reduction (to £6.9m from £27.2m in H117) while growing the commercial infrastructure that now includes China. Investors should see a path to profitability, but we note recent licensing opportunities in the respiratory therapeutic area could accelerate this.

09 Nov 2018
Circassia Pharmaceuticals - Joining the dots

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Circassia Pharmaceuticals - Joining the dots
NIOX Group Plc (NIOX:LON) | 63.5 0 0.0% | Mkt Cap: 267.2m
- Published:
09 Nov 2018 -
Author:
Dr Andy Smith -
Pages:
2 -
Circassia’s recent interims demonstrated 55% y-o-y revenue growth to £28.4m and a 75% R&D expense reduction (to £6.9m from £27.2m in H117) while growing the commercial infrastructure that now includes China. Investors should see a path to profitability, but we note recent licensing opportunities in the respiratory therapeutic area could accelerate this.